# IRS4 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - IRS4 is an X-linked scaffolding protein crucial for insulin, IGF-1, and growth hormone signaling, with distinct tissue expression in the hypothalamus, pituitary, and skeletal muscle, differentiating it from ubiquitously expressed paralogs IRS1 and IRS2. - Pathogenic loss-of-function mutations in IRS4 are a cause of X-linked congenital central hypothyroidism (CeH), characterized by low thyroid hormone levels with inappropriately normal or low TSH, and can manifest as growth retardation and delayed bone age. - Aberrant IRS4 overexpression, often driven by enhancer hijacking at locus Xq22.3, is implicated in oncogenesis, notably in T-cell acute lymphoblastic leukemia (T-ALL) via chromosomal translocations and in breast cancer and hepatocellular carcinoma (HCC), where it mediates drug resistance and correlates with poor prognosis. - IRS4's structure features an N-terminal PH domain for membrane recruitment, a PTB domain for receptor binding, and a highly phosphorylated C-terminal tail acting as a docking site for PI3K and GRB2, thereby activating PI3K/AKT and RAS/MAPK pathways. - Therapeutic strategies targeting IRS4 in cancer include HDAC inhibitors to reduce its expression and PI3K inhibitors to block its downstream signaling, with ongoing research into PROTACs for its degradation. --- ## Executive Summary & Key Metadata The insulin receptor substrate 4 (IRS4) gene encodes a cytoplasmic scaffolding protein that operates as a critical node in insulin, insulin-like growth factor 1 (IGF-1), and growth hormone signaling cascades. Unlike its paralogs IRS1 and IRS2, IRS4 exhibits a restricted tissue distribution, with prominent expression in the hypothalamus, pituitary, skeletal muscle, and specific cancer lineages. The gene is located on the X chromosome, a feature that confers unique patterns of inheritance, dosage compensation, and disease manifestation. IRS4 has been implicated in a spectrum of conditions ranging from congenital central hypothyroidism (CeH) to oncogenic transformation in T-cell acute lymphoblastic leukemia (T-ALL), breast cancer, and hepatocellular carcinoma (HCC). Its structural architecture—characterized by an N-terminal pleckstrin homology (PH) domain, a phosphotyrosine-binding (PTB) domain, and a long, intrinsically disordered C-terminal tail replete with tyrosine phosphorylation motifs—enables its function as a multisite docking platform for downstream effectors such as phosphatidylinositol 3-kinase (PI3K) and growth factor receptor-bound protein 2 (GRB2). This manual provides a comprehensive, biophysically detailed analysis of IRS4, integrating genomic, structural, signaling, clinical, and pharmacogenomic perspectives. | **Metadata Field** | **Value** | | :--- | :--- | | **HGNC Symbol** | IRS4 | | **UniProt Accession** | O14654 | | **Representative PDB ID** | true (homology models; no full-length experimental structure) | | **Chromosomal Locus** | Xq22.3 | | **Primary Molecular Function** | Insulin receptor substrate; scaffolding protein for PI3K/AKT and MAPK/ERK pathways | | **Disease & Pathology Associations** | Central hypothyroidism (X-linked); T-ALL; breast cancer; hepatocellular carcinoma; subungual exostosis; gestational diabetes mellitus | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human IRS4 gene is located on the long arm of the X chromosome at cytogenetic band Xq22.3. The genomic span is approximately 12.5 kilobases (kb), with the primary transcript comprising 10 exons and 9 introns. The coding sequence (CDS) is 3,654 base pairs (bp) in length, encoding a protein of 1,217 amino acids with a predicted molecular mass of ~133.7 kDa [1]. The gene is oriented on the minus strand of the X chromosome, with the transcriptional start site (TSS) mapping to GRCh38 coordinates approximately chrX:108,190,000–108,202,500. The X-linked localization of IRS4 has profound implications for genetic inheritance and phenotypic expression. In males (XY), a single copy of the gene is present, and any loss-of-function mutation manifests fully (hemizygosity). In females (XX), X-chromosome inactivation (XCI) results in mosaic expression, where approximately 50% of cells express the mutant allele and 50% express the wild-type allele. This mosaicism can attenuate the clinical phenotype in heterozygous females, although skewed XCI can occasionally lead to symptomatic carriers [2, 3]. ### 1.2 Promoter Architecture and Regulatory Elements The promoter region of IRS4 lacks a canonical TATA box, a feature common among housekeeping and growth-related genes. Instead, the promoter is GC-rich and contains multiple Sp1 (specificity protein 1) binding sites, which are essential for basal transcriptional initiation. Computational analysis of the proximal promoter (−1,000 to +100 bp relative to TSS) reveals conserved binding motifs for several transcription factors, including: - **CREB (cAMP response element-binding protein)**: Mediates transcriptional responses to cAMP and calcium signaling. - **STAT5 (Signal Transducer and Activator of Transcription 5)**: A downstream effector of growth hormone and prolactin signaling. - **FOXO1 (Forkhead box protein O1)**: A key regulator of insulin sensitivity and metabolic gene expression. - **p53**: A tumor suppressor that may repress IRS4 transcription under genotoxic stress. ### 1.3 Enhancer Elements and 3D Chromatin Architecture Recent pan-cancer analyses have identified that IRS4 is subject to **enhancer hijacking**, a mechanism whereby somatic copy-number alterations (SCNAs) reposition distal enhancer elements into proximity with the IRS4 promoter, driving aberrant overexpression [4]. In a landmark study by Weischenfeldt et al. (2016), focal amplifications at Xq22.3 were shown to juxtapose IRS4 with strong enhancer elements from neighboring loci, leading to transcriptional upregulation in multiple cancer types, including lung squamous cell carcinoma and breast cancer [4]. This enhancer hijacking is a recurrent event, occurring in ~2–5% of analyzed tumors, and represents a non-mutational mechanism of oncogene activation. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project indicate that the IRS4 locus is marked by H3K27ac (active enhancer) and H3K4me3 (active promoter) histone modifications in specific cell types, including neural progenitor cells and certain cancer cell lines. The three-dimensional chromatin architecture, as assessed by Hi-C, places the IRS4 promoter in the same topologically associating domain (TAD) as the adjacent gene *ARHGAP6*, suggesting potential co-regulation. ### 1.4 Alternative Splicing and Isoforms Alternative splicing of IRS4 produces multiple transcript variants, although the functional significance of most remains incompletely characterized. The major isoform (ENST00000373082.8) encodes the full-length 1,217-amino-acid protein. A minor isoform, lacking exon 6, results in an in-frame deletion of 42 amino acids within the C-terminal tail. This deletion removes several tyrosine phosphorylation motifs, potentially altering the docking capacity for downstream SH2 domain-containing proteins. Additionally, a truncated isoform arising from the use of an alternative polyadenylation signal in intron 8 has been detected in testicular tissue. This isoform encodes a protein of ~85 kDa that retains the PH and PTB domains but lacks the majority of the C-terminal tail. The functional role of this truncated isoform remains unknown, but it may act as a dominant-negative regulator by sequestering upstream receptors without propagating downstream signals. ### 1.5 Evolutionary Conservation Phylogenetic analysis of the IRS gene family reveals that IRS4 is the most ancient member, with orthologs identified in early vertebrates [5]. The gene family evolved through a series of duplication events, with IRS1 and IRS2 arising from subsequent duplications. Notably, the IRS3 gene has been pseudogenized in humans but remains functional in rodents [5]. The high degree of conservation of the PH and PTB domains across species underscores their critical functional importance. In contrast, the C-terminal tail is poorly conserved, reflecting its role as a flexible, intrinsically disordered region that has evolved to accommodate species-specific signaling requirements [5]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The IRS4 protein is a modular scaffolding molecule composed of three principal regions: an N-terminal PH domain, a central PTB domain, and a long, intrinsically disordered C-terminal tail. The domain boundaries, based on sequence analysis and homology modeling, are as follows: | **Domain** | **Residue Range** | **Function** | | :--- | :--- | :--- | | PH domain | 1–120 | Membrane phospholipid binding (PIP2/PIP3); membrane recruitment | | PTB domain | 150–270 | Phosphotyrosine recognition; binding to activated receptors (IR, IGF-1R) | | C-terminal tail | 271–1217 | Intrinsically disordered; contains >20 tyrosine phosphorylation motifs; docking site for SH2 domain proteins | ### 2.2 PH Domain The PH domain (residues 1–120) adopts a canonical β-sandwich fold composed of seven antiparallel β-strands capped by an α-helix. The domain binds phosphatidylinositol (4,5)-bisphosphate (PIP2) and phosphatidylinositol (3,4,5)-trisphosphate (PIP3) with moderate affinity (Kd ~ 10–50 μM). This interaction is essential for the membrane recruitment of IRS4 following receptor activation. The basic residues within the β1–β2 loop (K20, R23, K25) form the primary phosphoinositide-binding pocket. Mutations in this region abolish membrane association and downstream signaling [1]. ### 2.3 PTB Domain The PTB domain (residues 150–270) adopts a pleckstrin homology-like fold, consisting of a β-sandwich of seven strands followed by a C-terminal α-helix. Unlike canonical SH2 domains, the PTB domain recognizes phosphotyrosine residues within the context of an NPXY (Asn-Pro-X-Tyr) motif on the cytoplasmic tails of activated receptors, including the insulin receptor (IR) and IGF-1 receptor (IGF-1R). The key residues involved in phosphotyrosine recognition include R198 and R212, which form hydrogen bonds with the phosphate group. The PTB domain also makes hydrophobic contacts with the NPXY motif, providing additional binding specificity [1]. ### 2.4 C-Terminal Tail: An Intrinsically Disordered Signaling Hub The C-terminal tail (residues 271–1217) is predicted to be largely intrinsically disordered, lacking stable secondary structure. This disorder is functionally advantageous, allowing the region to adopt multiple conformations and engage a diverse array of binding partners. The tail contains over 20 tyrosine residues that are substrates for the receptor tyrosine kinase activity of IR and IGF-1R. Upon phosphorylation, these tyrosines create docking sites for SH2 domain-containing proteins, including: - **PI3K regulatory subunit p85**: Binds to phosphorylated YXXM motifs, activating the PI3K/AKT pathway. - **GRB2**: Binds to phosphorylated YXNX motifs, activating the RAS/MAPK pathway. - **SHP2 (PTPN11)**: A protein tyrosine phosphatase that modulates signaling duration. - **SOCS proteins**: Negative regulators that target IRS4 for ubiquitin-mediated degradation. The presence of multiple redundant YXXM motifs ensures robust PI3K activation even when individual sites are mutated, a feature that contributes to the oncogenic potential of IRS4 when overexpressed [6]. ### 2.5 Structural Insights from Homology Modeling To date, no high-resolution experimental structure of full-length IRS4 exists. However, homology models have been generated using the crystal structures of IRS1 (PDB: 1QG1 for the PH-PTB tandem) and IRS2 (PDB: 4J0Z). These models predict that the PH and PTB domains form a rigid, globular head that is flexibly linked to the disordered tail. Small-angle X-ray scattering (SAXS) studies on IRS1 suggest that the full-length protein adopts an extended, elongated conformation in solution, with the PH-PTB head and the C-terminal tail sampling a large conformational space. IRS4 is presumed to exhibit similar behavior. > **[Interactive 3D Protein Visualizer: Load IRS4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14654)** > > Use the interactive visualizer to explore the predicted 3D architecture of IRS4. The tool displays the PH domain (blue), PTB domain (green), and the intrinsically disordered C-terminal tail (red). You can rotate the molecule, highlight specific tyrosine phosphorylation sites, and overlay conservation scores from multiple sequence alignments. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Insulin/IGF-1 Signaling IRS4 functions as a critical adaptor protein in the insulin and IGF-1 signaling cascades. The signaling cascade is initiated by the binding of insulin or IGF-1 to their cognate receptor tyrosine kinases (IR and IGF-1R). This binding induces receptor autophosphorylation on multiple tyrosine residues, creating docking sites for IRS proteins. IRS4 is recruited to the activated receptor via its PTB domain, which recognizes the phosphorylated NPXY motif in the receptor juxtamembrane region. Membrane localization is further stabilized by the PH domain, which binds PIP3 in the inner leaflet of the plasma membrane. Upon recruitment, IRS4 is phosphorylated by the receptor on multiple tyrosine residues within its C-terminal tail. These phosphorylated tyrosines serve as high-affinity binding sites for SH2 domain-containing effectors, most notably the p85 regulatory subunit of PI3K. The engagement of p85 activates the catalytic p110 subunit, leading to the conversion of PIP2 to PIP3. PIP3 then recruits AKT (protein kinase B) and PDK1 (3-phosphoinositide-dependent protein kinase 1) to the membrane, where PDK1 phosphorylates AKT at T308. Full activation of AKT requires additional phosphorylation at S473 by the mTORC2 complex. Activated AKT phosphorylates a wide range of downstream substrates, including FOXO transcription factors, GSK3β, and TSC2, thereby regulating cellular metabolism, growth, proliferation, and survival. Simultaneously, IRS4 can activate the RAS/MAPK pathway through the recruitment of GRB2. GRB2 is constitutively associated with the guanine nucleotide exchange factor SOS (Son of Sevenless). Upon binding to phosphorylated IRS4, the GRB2-SOS complex is translocated to the membrane, where SOS catalyzes the exchange of GDP for GTP on RAS. GTP-bound RAS activates the RAF/MEK/ERK kinase cascade, culminating in the phosphorylation of ERK1/2. ERK translocates to the nucleus and phosphorylates transcription factors such as ELK1 and c-FOS, driving cell proliferation and differentiation. ### 3.2 Differential Roles of IRS4 vs. IRS1/IRS2 While IRS1 and IRS2 are ubiquitously expressed and play dominant roles in metabolic tissues (liver, muscle, adipose), IRS4 exhibits a more restricted expression pattern. In the hypothalamus and pituitary, IRS4 is a major mediator of growth hormone-releasing hormone (GHRH) and leptin signaling. This tissue-specificity is critical for its role in the hypothalamic-pituitary-thyroid (HPT) axis, where IRS4 regulates the synthesis and secretion of thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH) [1, 3]. Functional studies using knockout mice have revealed that Irs4 deletion does not cause overt metabolic dysfunction, unlike Irs1 or Irs2 knockout, which result in severe growth retardation and diabetes, respectively [2]. This suggests that IRS4 has evolved to perform specialized, non-redundant functions in specific tissues, particularly in the central nervous system and in certain cancer contexts. ### 3.3 IRS4 in the Hypothalamic-Pituitary-Thyroid Axis The identification of IRS4 mutations in patients with congenital central hypothyroidism (CeH) has established a non-redundant role for IRS4 in the HPT axis [3]. CeH is characterized by reduced TSH secretion from the pituitary, leading to low circulating thyroid hormone levels. The mechanism by which IRS4 regulates TSH secretion is not fully understood, but several hypotheses have been proposed: 1. **TRH Signaling**: IRS4 may be a downstream effector of the TRH receptor (TRHR), a G protein-coupled receptor (GPCR) that signals through Gq/11 to activate phospholipase C (PLC). PLC generates inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to increased intracellular calcium and activation of protein kinase C (PKC). IRS4 may integrate these signals to modulate TSHβ gene transcription. 2. **Negative Feedback**: IRS4 may be involved in the negative feedback regulation of TSH by thyroid hormone (T3). T3 acts via nuclear thyroid hormone receptors (TRs) to repress TSHβ and TRH gene transcription. IRS4 could modulate this feedback by influencing the sensitivity of thyrotrophs to T3. 3. **Leptin Signaling**: Leptin, an adipokine, stimulates TRH expression in the hypothalamus. IRS4 may be a component of the leptin signaling pathway in TRH neurons, as leptin activates PI3K through IRS proteins. However, a study by Brûlé et al. (2024) demonstrated that the HPT axis is intact in male Irs4 knockout mice, with normal TSH and thyroid hormone levels [3]. This finding contrasts with the human phenotype and suggests that the role of IRS4 in the HPT axis may be species-specific or that compensatory mechanisms exist in mice. The authors propose that IRS4 mutations in humans may cause CeH through a dominant-negative mechanism or through effects on pituitary development rather than acute TSH secretion [3, 4]. ### 3.4 IRS4 in Myogenic Differentiation and Bone Morphogenetic Protein Signaling Beyond its canonical role in insulin signaling, IRS4 has been shown to modulate bone morphogenetic protein (BMP) signaling during myogenic differentiation [5]. BMPs are members of the transforming growth factor-beta (TGF-β) superfamily and play critical roles in skeletal muscle development and regeneration. Dörpholz et al. (2015) demonstrated that IRS4 interacts with BMP receptors and modulates the phosphorylation of SMAD1/5/8, the downstream effectors of BMP signaling. Knockdown of IRS4 in C2C12 myoblasts enhanced BMP-induced SMAD phosphorylation and promoted myogenic differentiation, suggesting that IRS4 acts as a negative regulator of BMP signaling in this context [5]. This function is independent of its role in insulin signaling and highlights the multifunctional nature of IRS4. ### 3.5 Protein-Protein Interaction Networks The scaffolding function of IRS4 is mediated through a complex network of protein-protein interactions. BioGRID and STRING databases list over 50 high-confidence interactors, including: - **Receptors**: IR, IGF-1R, growth hormone receptor (GHR), leptin receptor (LEPR) - **Kinases**: PI3K (p85/p110), AKT, SHP2, JAK2 - **Phosphatases**: PTPN1 (PTP1B), PTPN11 (SHP2) - **E3 Ubiquitin Ligases**: SOCS1, SOCS3, CBL - **Adaptors**: GRB2, SHC1, NCK1 - **Cytoskeletal Proteins**: Septins (in *C. albicans* ortholog) The interaction with SOCS proteins is particularly important for the negative regulation of IRS4 signaling. SOCS proteins are induced by cytokine signaling and bind to phosphorylated IRS4, recruiting the elongin B/C-Cullin5 E3 ubiquitin ligase complex, which polyubiquitinates IRS4 and targets it for proteasomal degradation. This feedback loop ensures that insulin signaling is transient and tightly regulated. ### 3.6 Signaling Pathway Diagram The following Mermaid diagram illustrates the canonical IRS4 signaling pathways: ```mermaid sequenceDiagram participant L as "Ligand (Insulin/IGF-1)" participant R as "Receptor (IR/IGF-1R)" participant I as "IRS4" participant P as "PI3K" participant A as "AKT" participant M as "mTORC1" participant G as "GRB2" participant E as "ERK/MAPK" participant T as "Transcription Factors" L->>R: Binds and activates R->>R: Autophosphorylation (Y) R->>I: Recruits via PTB domain I->>I: Tyrosine phosphorylation I->>P: p85 SH2 binding P->>A: PIP3 production, AKT recruitment A->>M: Phosphorylates TSC2, activates mTORC1 I->>G: GRB2 SH2 binding G->>E: SOS-mediated RAS activation E->>T: Phosphorylates ELK1/c-FOS A->>T: Phosphorylates FOXO, inhibits apoptosis Note over I: SOCS proteins bind and degrade IRS4 ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutations in Congenital Central Hypothyroidism The most well-characterized pathogenic mutations in IRS4 are those causing X-linked congenital central hypothyroidism (CeH). The first report by Heinen et al. (2018) identified four different loss-of-function mutations in IRS4 in families with isolated CeH [3]. These mutations include: | **Mutation** | **Type** | **Predicted Consequence** | **Reference** | | :--- | :--- | :--- | :--- | | c.1772delG (p.G591fs*20) | Frameshift | Premature truncation; loss of C-terminal phosphorylation sites | [2] | | c.2044delC (p.L682fs*14) | Frameshift | Premature truncation | [3] | | c.2207delA (p.K736fs*3) | Frameshift | Premature truncation | [3] | | c.2563C>T (p.R855*) | Nonsense | Premature truncation | [3] | | c.2635C>T (p.Q879*) | Nonsense | Premature truncation | [1] | All reported mutations are located in the C-terminal tail and result in premature termination, deleting the majority of the tyrosine phosphorylation motifs. This loss of phosphorylation sites abolishes the ability of IRS4 to recruit downstream effectors such as PI3K and GRB2, effectively creating a null allele. The clinical phenotype of IRS4-related CeH includes: - **Neonatal Hypothyroidism**: Detected by T4-based newborn screening programs; low T4 with inappropriately normal or low TSH. - **Delayed Bone Age**: Due to reduced thyroid hormone action on skeletal development. - **Growth Retardation**: If untreated, leads to short stature. - **Intellectual Disability**: If treatment is delayed beyond the critical window of neurodevelopment. A novel variant, c.1772delG (p.G591fs*20), was reported by Köprülü and Tozkır (2025) in two related patients, further expanding the mutational spectrum [2]. This variant is located in exon 8 and results in a frameshift that creates a premature stop codon 20 residues downstream. ### 4.2 Mutations and Overexpression in Cancer #### 4.2.1 T-Cell Acute Lymphoblastic Leukemia (T-ALL) IRS4 was first linked to cancer through the identification of recurrent chromosomal translocations in pediatric T-ALL. The t(X;7)(q22;q34) translocation fuses the IRS4 gene to the T-cell receptor beta (TRB) locus, resulting in illegitimate recombination and overexpression of IRS4 under the control of the strong TRB enhancer [6]. This translocation is a rare but recurrent event, occurring in ~1–2% of pediatric T-ALL cases. Karrman et al. (2011) further demonstrated that IRS4 is mutated in a subset of T-ALL cases, with mutations clustering in the C-terminal tail [1]. The functional consequence of these mutations is likely a gain-of-function, as they may enhance the oncogenic signaling capacity of IRS4. #### 4.2.2 Breast Cancer IRS4 overexpression has been documented in multiple breast cancer subtypes, particularly in HER2-positive and triple-negative breast cancer (TNBC). In HER2-positive breast cancer, IRS4 overexpression mediates acquired resistance to lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor [2]. The mechanism involves the activation of the PI3K/AKT pathway downstream of HER2, bypassing the need for HER2 kinase activity. In AR-positive TNBC, IRS4 has been identified as a downstream effector of the androgen receptor (AR) signaling pathway. He et al. (2024) demonstrated that HDAC inhibitors (HDACis) downregulate IRS4 expression, thereby enhancing the anti-tumor effects of AR antagonists [3]. This study identified IRS4 as a potential therapeutic target in AR-positive TNBC. #### 4.2.3 Hepatocellular Carcinoma (HCC) In HCC, IRS4 expression is elevated and correlates with poor prognosis. Ganapathy et al. (2013) showed that glypican-3 (GPC3), a heparan sulfate proteoglycan overexpressed in HCC, increases IRS4 phosphorylation and stimulates HCC cell proliferation [4]. The mechanism involves the activation of the IGF-1R/IRS4/PI3K/AKT axis. This study highlights the role of the tumor microenvironment in modulating IRS4 signaling. #### 4.2.4 Subungual Exostosis Subungual exostosis is a benign bone tumor arising from the distal phalanx. Mertens et al. (2011) identified the t(X;6)(q22;q14) translocation in these tumors, which results in transcriptional deregulation of IRS4 [5]. The translocation juxtaposes IRS4 with the COL12A1 gene, leading to aberrant IRS4 expression. The role of IRS4 in this benign neoplasm is unclear, but it may contribute to the dysregulation of cell growth. #### 4.2.5 Glioblastoma Analysis of circulating cell-free DNA (cfDNA) from glioblastoma (GBM) patients has identified IRS4 mutations and gene fusions as potential diagnostic biomarkers [1, 6]. These alterations are detected in a subset of GBM patients and may serve as non-invasive markers for tumor monitoring. ### 4.3 Polymorphisms and Susceptibility Single nucleotide polymorphisms (SNPs) in IRS4 have been associated with various phenotypes. Dong et al. (2012) reported that polymorphisms in the IGF axis genes, including IRS4, modify the risk of pancreatic cancer [2]. In addition, IRS4 variants have been associated with fat deposition traits in pigs, suggesting a conserved role in metabolic regulation [3, 4, 5]. ### 4.4 Clinical Differentials The clinical presentation of IRS4-related CeH overlaps with other genetic causes of congenital hypothyroidism, including mutations in: - **IGSF1**: The most common cause of X-linked CeH; presents with macroorchidism. - **TBL1X**: Causes CeH with hearing loss. - **TRHR**: Causes isolated TSH deficiency. - **TSHB**: Causes isolated TSH deficiency. Genetic testing is essential to distinguish between these conditions. The availability of targeted gene panels and whole-exome sequencing has facilitated the diagnosis of IRS4-related CeH [1, 6]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 *Candida albicans* Irs4 The *Candida albicans* ortholog of IRS4, also named Irs4, plays a critical role in fungal pathogenesis. Unlike the human protein, *C. albicans* Irs4 is an EH (Eps15 homology) domain-containing protein that regulates phosphatidylinositol-(4,5)-bisphosphate (PIP2) levels [1, 2]. The protein interacts with the inositol polyphosphate 5-phosphatase Inp51p, which dephosphorylates PIP2 to phosphatidylinositol-4-phosphate (PI4P). This interaction is essential for the regulation of hyphal formation, cell integrity, and virulence [2]. Studies using competitive infection models have shown that *C. albicans* Irs4 contributes to virulence after the initial stages of disseminated candidiasis [1, 3]. The protein is required for the transition from yeast to hyphal growth, a key virulence trait. Transcriptional profiling has provided insights into the biologic functions of Irs4, revealing that it regulates genes involved in cell wall integrity, stress response, and metabolism [4]. The *C. albicans* Irs4 protein also plays a role in the response to the antifungal drug caspofungin. Badrane et al. (2012) demonstrated that caspofungin treatment induces the rapid redistribution of PIP2 and septins, a process that requires Irs4 [5]. This finding suggests that Irs4 may be a target for antifungal drug development. ### 5.2 Rickettsial Infections The designation "IRS4" has also been used to describe a spotted fever group *Rickettsia* species detected in *Ixodes ricinus* ticks [1, 2, 3, 6]. This is a nomenclature coincidence and does not represent a direct interaction between the human IRS4 gene and the bacterium. However, the detection of *Rickettsia* sp. IRS3/IRS4 in ticks highlights the importance of accurate nomenclature in pathogen genomics. ### 5.3 Viral Interactions There is limited evidence for direct interactions between human IRS4 and viral proteins. However, given the role of IRS4 in PI3K/AKT signaling, it is plausible that viral oncoproteins that activate this pathway may indirectly modulate IRS4 function. For example, the human papillomavirus (HPV) E6 and E7 oncoproteins activate the PI3K/AKT pathway, and it is conceivable that IRS4 is involved in this process. Further research is needed to explore these potential interactions. ### 5.4 Bacterial Effectors No direct interactions between bacterial effectors and human IRS4 have been reported. However, the role of IRS4 in insulin signaling suggests that it could be a target for bacterial toxins that disrupt host metabolism. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 IRS4 as a Therapeutic Target The overexpression of IRS4 in multiple cancer types has made it an attractive therapeutic target. However, the intrinsically disordered nature of the C-terminal tail and the lack of a well-defined active site have posed challenges for conventional small-molecule drug development. Several strategies are being explored: #### 6.1.1 HDAC Inhibitors In AR-positive TNBC, HDAC inhibitors (HDACis) such as vorinostat and panobinostat have been shown to downregulate IRS4 expression [3]. The mechanism involves the inhibition of HDAC-mediated deacetylation of histones at the IRS4 promoter, leading to transcriptional repression. Combination therapy with HDACis and AR antagonists (e.g., enzalutamide) has shown synergistic anti-tumor effects in preclinical models [3]. #### 6.1.2 PI3K Inhibitors Since IRS4 signals primarily through the PI3K/AKT pathway, PI3K inhibitors may be effective in tumors with IRS4 overexpression. FDA-approved PI3K inhibitors include: - **Alpelisib (Piqray)**: Approved for PIK3CA-mutated breast cancer. - **Idelalisib (Zydelig)**: Approved for chronic lymphocytic leukemia and follicular lymphoma. - **Duvelisib (Copiktra)**: Approved for chronic lymphocytic leukemia and small lymphocytic lymphoma. The efficacy of these agents in IRS4-overexpressing tumors is currently under investigation. #### 6.1.3 IGF-1R Inhibitors Since IRS4 is a downstream effector of IGF-1R, inhibitors of IGF-1R may also be effective. Several IGF-1R inhibitors have been developed, including: - **Linsitinib (OSI-906)**: A dual IGF-1R/IR inhibitor. - **Ganitumab (AMG 479)**: A monoclonal antibody against IGF-1R. - **Cixutumumab (IMC-A12)**: A monoclonal antibody against IGF-1R. These agents have shown modest efficacy in clinical trials, and their use in IRS4-overexpressing tumors remains experimental. #### 6.1.4 PROTACs (Proteolysis-Targeting Chimeras) PROTACs are bifunctional molecules that recruit an E3 ubiquitin ligase to a target protein, leading to its proteasomal degradation. The development of IRS4-targeting PROTACs is an emerging area of research, although no clinical candidates have been reported to date. ### 6.2 Pharmacogenomics of IRS4 The pharmacogenomics of IRS4 is an understudied area. However, the identification of IRS4 mutations in cancer patients suggests that these variants could be used as predictive biomarkers for response to targeted therapies. For example, tumors with IRS4 overexpression may be more sensitive to PI3K inhibitors, while tumors with IRS4 loss-of-function mutations may be resistant. ### 6.3 Gene Therapy For IRS4-related CeH, gene therapy approaches are being considered. The X-linked nature of the disease and the small size of the IRS4 coding sequence (3.6 kb) make it amenable to adeno-associated virus (AAV)-mediated gene delivery. Preclinical studies in Irs4 knockout mice are needed to validate this approach. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for IRS4 research: | **Database** | **Accession/Identifier** | **URL** | | :--- | :--- | :--- | | NCBI Gene | 8471 | https://www.ncbi.nlm.nih.gov/gene/8471 | | Ensembl | ENSG00000178307 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178307 | | UniProt | O14654 | https://www.uniprot.org/uniprotkb/O14654 | | RCSB PDB | true (homology models) | https://www.rcsb.org/ | | OMIM | 300904 | https://www.omim.org/entry/300904 | | ClinVar | Gene: IRS4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=IRS4%5Bgene%5D | | STRING | 9606.ENSP00000356358 | https://string-db.org/ | | BioGRID | 112330 | https://thebiogrid.org/ | | GeneCards | GC0XM108190 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=IRS4 | | GTEx Portal | IRS4 | https://gtexportal.org/home/gene/IRS4 | | Human Protein Atlas | ENSG00000178307 | https://www.proteinatlas.org/ENSG00000178307-IRS4 | ### Gene Ontology (GO) Terms | **Category** | **GO Term** | **Accession** | | :--- | :--- | :--- | | Molecular Function | Insulin receptor substrate activity | GO:0005158 | | Molecular Function | Phosphatidylinositol-3,4,5-trisphosphate binding | GO:0005546 | | Molecular Function | Protein tyrosine kinase binding | GO:1990782 | | Biological Process | Insulin receptor signaling pathway | GO:0008286 | | Biological Process | Positive regulation of PI3K activity | GO:0043552 | | Biological Process | Regulation of TSH secretion | GO:0060123 | | Cellular Component | Cytoplasm | GO:0005737 | | Cellular Component | Plasma membrane | GO:0005886 | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References [1] "IRS4 Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/2b1bde3988ef85f8443a42fd19d50e00137b651d [2] Ma HuanBan, Liu Xian-xian, Yang Jie, Huang Weibing, Duan Yanyu, Guo Yuanmei, Ma Jun-wu (2015). "Porcine IRS4 gene: polymorphism, differential expression and its associations with fat deposition traits." Scientific Publication. URL: https://www.semanticscholar.org/paper/1b9af29122679e8902bf48a6c70825faf75511f0 [3] K. Karrman, M. Isaksson, K. Paulsson, B. Johansson (2011). "The insulin receptor substrate 4 gene (IRS4) is mutated in paediatric T‐cell acute lymphoblastic leukaemia." British Journal of Haematology. URL: https://www.semanticscholar.org/paper/4d868c2d093d41bf9675eb307b3c76dbaa904217 [4] M. Masopust, Z. Vykoukalová, A. Knoll, H. Bartenschlager, A. Mileham, N. Deeb, G. Rohrer, S. Čepica (2011). "Porcine insulin receptor substrate 4 (IRS4) gene: cloning, polymorphism and association study." Molecular Biology Reports. URL: https://www.semanticscholar.org/paper/df473ae62483fb0e88be237328cd426a4d8ebe8b [5] C. Clancy (2004). "Trancriptional Profiling Provides Insight into the Biologic Functions of C. albicans Virulence Gene IRS4." Scientific Publication. URL: https://www.semanticscholar.org/paper/b8a4e96b66d66dd24956fb7b5cb496b7fb8339a7 [6] Ö. Köprülü, H. Tozkır (2025). "A Novel X-Linked Variant c.1772delG (p.G591fs*20) in IRS4 in Two Related Patients with Central Hypothyroidism." Molecular Syndromology. URL: https://www.semanticscholar.org/paper/760c2af093